Alan Robinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alan Robinson has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Cenfu Wei
Division of Gastroenterology and Hepatology, Feinberg School of Medicine, Northwestern University, Chicago, USA
2 shared publications Isabella Peshek
Division of Gastroenterology and Hepatology, Feinberg School of Medicine, Northwestern University, Chicago, USA
2 shared publications- Parambir S. Dulai
Division of Gastroenterology and Hepatology, Feinberg School of Medicine, Northwestern University, Chicago, USA
2 shared publications Aakash Desai
Division of Gastroenterology, Hepatology & Nutrition, Allegheny Health Network, Pittsburgh, USA
1 shared publicationBanishree Saha
Translational Medicine and Biomarker Research (Early Clinical Development), Gastrointestinal and Inflammation Therapeutic Area Unit, Takeda Development Center Americas, Cambridge, USA
1 shared publicationChristian Agboton
Global Medical Affairs, Takeda, Cambridge, USA
1 shared publication
Latest Publications
- Open Access
- 9 November 2026
- Published by Springer Nature in Nature Medicine
- p. 1-12
An ulcerative colitis taxonomy defined by individual patient-reported response trajectories
A barrier to precision medicine for ulcerative colitis (UC) is the inability to predict and mechanistically explain treatment responses. Using patient-reported outcomes (PROs) from a phase 3b comparative trial of 768 participants, we identified four distinct patient response-trajectory groups for vedolizumab (anti-integrin) and adalimumab (antitumor necrosis factor). Validation in a second phase 3 trial of 576 participants linked PRO-defined vedolizumab trajectories to long-term disease complications. Bulk, single cell, and spatial transcriptomics and proteomics identified vascular inflammation as associated with vedolizumab nonresponse through interactions between SPP1 + macrophages and endothelial cells. In two separate real-world cohorts of 4,981 and 3,854 patients with UC, concomitant use of renin–angiotensin system inhibitors (modulators of vascular inflammation) was associated with reduced long-term complications for vedolizumab but not anticytokine therapies. These findings define a response-trajectory-based taxonomy that requires prospective validation for clinical utility and applications for selecting vedolizumab combination therapy in UC.
- 9 November 2026
- Published by Springer Nature in Nature Medicine
- p. 1-12
Open AccessAn ulcerative colitis taxonomy defined by individual patient-reported response trajectories
A barrier to precision medicine for ulcerative colitis (UC) is the inability to predict and mechanistically explain treatment responses. Using patient-reported outcomes (PROs) from a phase 3b comparative trial of 768 participants, we identified four distinct patient response-trajectory groups for vedolizumab (anti-integrin) and adalimumab (antitumor necrosis factor). Validation in a second phase 3 trial of 576 participants linked PRO-defined vedolizumab trajectories to long-term disease complications. Bulk, single cell, and spatial transcriptomics and proteomics identified vascular inflammation as associated with vedolizumab nonresponse through interactions between SPP1 + macrophages and endothelial cells. In two separate real-world cohorts of 4,981 and 3,854 patients with UC, concomitant use of renin–angiotensin system inhibitors (modulators of vascular inflammation) was associated with reduced long-term complications for vedolizumab but not anticytokine therapies. These findings define a response-trajectory-based taxonomy that requires prospective validation for clinical utility and applications for selecting vedolizumab combination therapy in UC.
- Open Access
- 28 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17
Spatial transcriptomics atlas of inflammatory bowel disease to guide implementation in research consortiums and clinical trials
Using over 100 intestinal tissue sections from non-diseased controls and patients with ulcerative colitis or Crohn’s disease across multiple inflammatory bowel disease consortia, we construct a spatially resolved atlas containing over three million cells and systematically evaluate two imaging-based spatial transcriptomics platforms. Here we show that CosMx tends to achieve higher detection efficiency than Xenium across commercially available panels in both ulcerative colitis and Crohn’s disease, whereas Xenium shows reduced performance associated with tissue type, block quality, and panel size. CosMx identifies regulatory T cell associated biology in both disease subtypes, which we validate using independent laboratory experiments and multi-plex spatial multi-omics. CosMx’s data quality remains stable across variation in fixation time and sectioning procedures, supporting its operational feasibility for multi-center studies. This study establishes a technical and biological benchmark for the application of single-cell-resolved spatial transcriptomics in gastrointestinal tissue, enabling more reliable application of spatial technologies in translational inflammatory bowel disease research.
- 28 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17
Open AccessSpatial transcriptomics atlas of inflammatory bowel disease to guide implementation in research consortiums and clinical trials
Using over 100 intestinal tissue sections from non-diseased controls and patients with ulcerative colitis or Crohn’s disease across multiple inflammatory bowel disease consortia, we construct a spatially resolved atlas containing over three million cells and systematically evaluate two imaging-based spatial transcriptomics platforms. Here we show that CosMx tends to achieve higher detection efficiency than Xenium across commercially available panels in both ulcerative colitis and Crohn’s disease, whereas Xenium shows reduced performance associated with tissue type, block quality, and panel size. CosMx identifies regulatory T cell associated biology in both disease subtypes, which we validate using independent laboratory experiments and multi-plex spatial multi-omics. CosMx’s data quality remains stable across variation in fixation time and sectioning procedures, supporting its operational feasibility for multi-center studies. This study establishes a technical and biological benchmark for the application of single-cell-resolved spatial transcriptomics in gastrointestinal tissue, enabling more reliable application of spatial technologies in translational inflammatory bowel disease research.